Altfest L J & Co. Inc. Has $534,000 Position in Celgene Corporation (CELG)

Altfest L J & Co. Inc. cut its stake in shares of Celgene Corporation (NASDAQ:CELG) by 5.6% during the second quarter, Holdings Channel reports. The fund owned 4,113 shares of the biopharmaceutical company’s stock after selling 246 shares during the period. Altfest L J & Co. Inc.’s holdings in Celgene Corporation were worth $534,000 as of its most recent filing with the SEC.

Other large investors have also added to or reduced their stakes in the company. State Street Corp raised its position in Celgene Corporation by 2.3% in the first quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock worth $4,040,668,000 after buying an additional 723,844 shares in the last quarter. Bank of New York Mellon Corp raised its position in Celgene Corporation by 4.9% in the first quarter. Bank of New York Mellon Corp now owns 10,088,473 shares of the biopharmaceutical company’s stock worth $1,255,309,000 after buying an additional 472,067 shares in the last quarter. American Century Companies Inc. raised its position in Celgene Corporation by 4.4% in the first quarter. American Century Companies Inc. now owns 6,563,791 shares of the biopharmaceutical company’s stock worth $816,733,000 after buying an additional 276,089 shares in the last quarter. Pioneer Investment Management Inc. raised its position in Celgene Corporation by 15.7% in the first quarter. Pioneer Investment Management Inc. now owns 5,231,139 shares of the biopharmaceutical company’s stock worth $650,911,000 after buying an additional 710,584 shares in the last quarter. Finally, Clearbridge Investments LLC raised its position in Celgene Corporation by 24.1% in the first quarter. Clearbridge Investments LLC now owns 4,601,919 shares of the biopharmaceutical company’s stock worth $572,617,000 after buying an additional 892,392 shares in the last quarter. 78.34% of the stock is owned by institutional investors and hedge funds.

Shares of Celgene Corporation (NASDAQ:CELG) traded up 0.74% during trading on Friday, hitting $128.53. 1,695,352 shares of the stock were exchanged. The firm has a market capitalization of $100.56 billion, a P/E ratio of 39.80 and a beta of 1.89. The firm has a 50 day moving average price of $133.85 and a 200 day moving average price of $124.82. Celgene Corporation has a 52 week low of $96.93 and a 52 week high of $139.00.

Celgene Corporation (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.61 by $0.21. The company had revenue of $3.27 billion for the quarter, compared to analyst estimates of $3.23 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The firm’s revenue was up 18.7% on a year-over-year basis. During the same period in the previous year, the firm posted $1.44 EPS. Analysts forecast that Celgene Corporation will post $7.32 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was first published by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://www.com-unik.info/2017/08/18/altfest-l-j-co-inc-has-534000-position-in-celgene-corporation-celg.html.

A number of research firms have weighed in on CELG. Jefferies Group LLC set a $154.00 target price on shares of Celgene Corporation and gave the stock a “buy” rating in a research report on Saturday, May 13th. Oppenheimer Holdings, Inc. reissued an “outperform” rating and set a $175.00 target price on shares of Celgene Corporation in a research report on Wednesday, August 9th. Vetr raised shares of Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $148.32 target price for the company in a research report on Wednesday. SunTrust Banks, Inc. reissued a “buy” rating and set a $150.00 target price on shares of Celgene Corporation in a research report on Friday, July 14th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $139.00 target price on shares of Celgene Corporation in a research report on Thursday, July 6th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, twenty-two have issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $147.00.

In related news, Director Gilla Kaplan sold 7,500 shares of Celgene Corporation stock in a transaction that occurred on Wednesday, August 2nd. The shares were sold at an average price of $134.52, for a total transaction of $1,008,900.00. Following the sale, the director now directly owns 76,301 shares of the company’s stock, valued at approximately $10,264,010.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ernest Mario sold 18,506 shares of Celgene Corporation stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $130.52, for a total transaction of $2,415,403.12. Following the sale, the director now directly owns 69,424 shares in the company, valued at $9,061,220.48. The disclosure for this sale can be found here. Insiders have sold a total of 253,761 shares of company stock worth $33,792,445 over the last ninety days. 0.95% of the stock is currently owned by insiders.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

What are top analysts saying about Celgene Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Celgene Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit